Page 1925 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

1352 Index

Public Health Service Panel on Cost- signs from more invasive monitoring, secular trends, 9t, 10
Effectiveness in Health and 321–322 statistical control charts for performance
Medicine, United States diagnosis of monitoring, 10
(PCEHM), 39 empirical, 324f, 326 sources of variability in, 11
Public reporting of quality metrics, 10–11 risk factors, 322, 323f Quality metrics, public reporting of, 10–11
Pulmonary angiography in diagnosing special problems in intensive-care unit, Quality of life, health-related, 104–105
pulmonary embolic disorders, 326 322, 323f Quality scale, 11
Pulmonary artery catheters, 24–25, 24t, tests, 323–326, 324f, 325t Questioning approach, learning and using, in
245–246, 456–457 epidemiology of, in intensive-care unit, critical care, 6
in burn patients, 1186 318–321 Quetiapine, 153
distal tip thermistor, 246 pathophysiology, 319–321, 319f, Q-wave myocardial infarction, 294
https://kat.cr/user/tahir99/
in diagnosing right heart syndromes, 312 320f, 321f
Pulmonary artery hypertension, 259 prophylaxis against venous R
Pulmonary artery occlusion pressure, 263 thromboembolism, 332–333 Rabies virus, 673
Pulmonary artery pressure, hypercapnia air embolism, 333–335 Radiography in diagnosing right heart
and, 317 fat embolism, 335–336, 335t syndromes, 311
Pulmonary barotrauma, 1321 special considerations Radiology, interventional, 209
Pulmonary capillary permeability, 1048–1049 chronic obstructive pulmonary RAMPART trial, 784
Pulmonary circulation disease, 332 Ramsay Hunt syndrome, 670
edema, 239–240, 240f patients with coagulation or platelet Ramsay Sedation Score, 148
pressures, flow, and resistance in disorders, 332 Randomized controlled trials, 45–46
pulmonary vessels, 238–239, 239f pregnancy, 332 Range of motion
Pulmonary crackles, 259 treatment of, 326–332 active, 163–164
Pulmonary edema, 239–240, 240f, 1048–1049 anticoagulation, 327–329 passive, 163
diagnosis and management of, 200–201 prognosis and intensity of, 326–327 Rapidly progressive glomerulonephritis, 922
Pulmonary effects, obesity and, 1307–1308 supportive care, 327 Rapid response teams, 77–83
Pulmonary embolic disorders. See Air Pulmonary toxicity, 894–896, 895t conditions reviewed and interventions
embolism; Fat embolism; Pulmonary vasodilator therapy, 259 performed, 81
Pulmonary thromboembolism Pulmonary venoocclusive disease, 895 deterioration of patients, 80, 81f
Pulmonary embolism, 221, 873–874, 873f Pulseless electrical activity, 170, 170t evidence for effectiveness of, 81–83, 82f
ECMO for, 481 Pulse oximetry, 243 nomenclature surrounding, 81
spinal injuries and, 1151 arterial blood gases and, 498 outcomes of cardiac arrests, 80
Pulmonary evaluation in organ Pulse pressure waveform analysis, 247–248 principles underlying, 80–81, 80f, 81t
transplantation, 1112–1113, 1112t Pump failure, 309 serious adverse events
Pulmonary fibrosis, 517–520 Pumpless, extracorporeal lung assist in hospitalized patients, 77, 78t
acute cardiopulmonary failure, 518 (PECLA), 471 preceded by signs of instability, 77,
cardiovascular management of, 519 Pupillary reflex, 833 78–79t, 79–80, 80f
detecting reversible features, 519, 519t Purpura, 1294, 1294t, 1295f Rate-based indicator, 8–9
effects on pulmonary circulation, 518 posttransfusion, 852 Rebleeding, 776
gas exchange, 518 Push enteroscopy, 1020–1021 Recluse spider bite, 1223
laboratory abnormalities, 517–518 Puumala virus, 742 Recombinant human activated protein C,
long-term management of idiopathic, 520 P values, 9, 46–47 sepsis and, 574
outcome, 518–519 confidence intervals, and power, 46–47 Recompression therapy, in decompression
oxygen therapy, 519 Pyelonephritis, emphysematous, 701 illness, 1322–1323, 1323f
respiratory mechanics, 518 Pyocystitis, 701 Red blood cell transfusions, 842
ventilator management of, 519–520 Pyonephrosis, 212, 700 in critical illness, 843
Pulmonary function abnormalities, 109 Pyuria, 696 during initial resuscitation, 252
Pulmonary gas exchange, abnormalities in, Reduced intensity conditioning (RIC), 603
372–373 Q Refractory angina, 298
Pulmonary hypertension, 312, 1103, 1307 Q fever, 751 Refractory hepatic hydrothorax, 223
acute-on-chronic, 314, 314t QRS complexes, 280 Refractory hypoxemia, 517
scleroderma and, 1243 Qualitative data, role in critical care research Refractory status epilepticus (RSE),
sickle cell disease and, 910–911, 911f and, 48 780, 785, 875
Pulmonary infiltrates in HIV-infected Quality Regionalization, 62
individuals, 636–638, 637–638t defining, 7 barriers in, 64, 64t
Pulmonary overpressurization, 1321 indicators in, 8–9, 8t evidence in, 63–64
Pulmonary resection surgery, evaluation of models of, 11 implementation strategies in, 64, 65ft
risk prior to, 1057–1058 reasons for measuring, 7–8 potential benefits in, 63
Pulmonary risk, clinical assessment of, Quality assurance, 3 role of intensivists in, 64
1057–1060 Quality indicators in critical care, 12–15, 14t special challenges in, 68
Pulmonary system, electrical trauma Quality measurement unintended consequences in, 63
and, 1178 research concepts relevant to, 9–10, 9t Regional techniques for analgesia,
Pulmonary thromboembolism, 318–333 bias in, 9, 9t 147–148
clinical manifestations chance, 9, 9t Regression to the mean, 9–10, 9t
history, examination, and laboratory confounding measures, 9t, 10 Rehabilitation, spinal injuries and, 1152
data, 321, 321t regression to the mean, 9–10, 9t Reliability, 85

Index.indd 1352 23-01-2015 15:33:53